drugset / Trial / NCT00086346

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

NCT00086346

Phase 3 Terminated 607 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.

Timeline

Start
2002-12
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide
Comparator Sirolimus Small molecule
Comparator Tacrolimus Small molecule

Indications

No indication recorded.